article thumbnail

RNA processing in health and disease: challenges and opportunities of the field

Drug Target Review

Hasson’s interest in drug discovery began early in his training, where he was able to work on chemical biology and microplate-based high throughput assays as a graduate student. After completing his postdoc, Sam undertook an industrial career in drug discovery, with an emphasis on neurodegenerative diseases, at Pfizer and then Amgen.

RNA 96
article thumbnail

New image-based cellular profiling tool peers deeply into metabolic biology

Broad Institute

Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. Fat cells stained yellow to show the actin cytoskeleton, plasma membrane, and Golgi apparatus. Credit: Phil Kubitz, Claussnitzer lab Fat cells stained blue to show nuclei. “I

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Taking a 3D view of heart failure with River BioMedics

Sygnature Discovery

We’re thrilled to be working with cutting-edge new Dutch biotech company River BioMedics to identify new drugs that directly treat heart failure and cardiovascular disease – the number one cause of death in the world. River BioMedics is progressing its cardiovascular disease programmes following a €1.8m

article thumbnail

Roche signs definitive share purchase agreement with long-term partner TIB.

The Pharma Data

TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche`s LightCycler PCR instruments.

Virus 52
article thumbnail

The hidden risks of over-reliance on healthy donor material

Drug Target Review

What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? Diseased cells are likely to be more fragile or less abundant, making it difficult to obtain enough for therapy.

article thumbnail

OTAT Town Hall on Cell Therapy CMC – The Recording is Available but Here’s an Appetizer

FDA Law Blog: Drug Discovery

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. Rising from Research Scientist to Senior Scientist, I supported early-stage DD efforts within their Protein Science group, based in Cambridge, UK.